Non-Small Cell Lung Cancer

Specialty Channel

News

Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer

08/19/2026

Emily Estrada

Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...

Results from the phase 2 DART...

08/19/2026

Oncology

News

Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer

08/11/2026

Emily Estrada

Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...

Ociperlimab plus tislelizumab...

08/11/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

News

Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer

06/26/2026

Emily Estrada

Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...

Results from a phase 2 module of...

06/26/2026

Oncology

News

Benmelstobart Plus Anlotinib as Potential New First-Line Option in Advanced NSCLC

05/29/2026

Emily Estrada

Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.

Benmelstobart plus chemotherapy...

05/29/2026

Oncology

News

Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer

05/29/2026

Stephanie Holland

Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.

Results from the phase 3...

05/29/2026

Oncology

News

Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer

05/27/2026

Emily Estrada

Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.

Updated results from the phase 3...

05/27/2026

Oncology

News

Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC

05/27/2026

Emily Estrada

Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.

Results from a multicenter phase...

05/27/2026

Oncology

FDA Approval

FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC

02/26/2026

Emily Estrada

Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.

Based on results from the...

02/26/2026

Oncology

News

Adjuvant Aumolertinib Improves Disease-Free Survival in Resected EGFR-Mutated Non–Small Cell Lung Cancer

01/21/2026

Stephanie Holland

Results from the phase 3 ARTS trial demonstrated that adjuvant aumolertinib significantly improved disease-free survival compared with placebo in patients with completely resected EGFR-mutated non-small cell lung cancer, supporting its use as...

Results from the phase 3 ARTS...

01/21/2026

Oncology

News

Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated Non-Small Cell Lung Cancer

01/13/2026

Stephanie Holland

Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...

Results from the phase 2 KANNON...

01/13/2026

Oncology

News

Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer

08/19/2026

Emily Estrada

Results from the phase 2 DART...

08/19/2026

Oncology

News

Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer

08/11/2026

Emily Estrada

Ociperlimab plus tislelizumab...

08/11/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

News

Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer

06/26/2026

Emily Estrada

Results from a phase 2 module of...

06/26/2026

Oncology

News

Benmelstobart Plus Anlotinib as Potential New First-Line Option in Advanced NSCLC

05/29/2026

Emily Estrada

Benmelstobart plus chemotherapy...

05/29/2026

Oncology

News

Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer

05/29/2026

Stephanie Holland

Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.

Results from the phase 3...

05/29/2026

Oncology

News

Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer

05/27/2026

Emily Estrada

Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.

Updated results from the phase 3...

05/27/2026

Oncology

News

Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC

05/27/2026

Emily Estrada

Results from a multicenter phase...

05/27/2026

Oncology

FDA Approval

FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC

02/26/2026

Emily Estrada

Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.

Based on results from the...

02/26/2026

Oncology

News

Adjuvant Aumolertinib Improves Disease-Free Survival in Resected EGFR-Mutated Non–Small Cell Lung Cancer

01/21/2026

Stephanie Holland

Results from the phase 3 ARTS...

01/21/2026

Oncology

Interactive Features

Quiz

Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

06/13/2024

True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.

True or False: Five-year...

06/13/2024

Oncology

Quiz

FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

05/29/2024

According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?

According to results from the...

05/29/2024

Oncology

Quiz

Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

04/04/2024

According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?

According to results from the...

04/04/2024

Oncology

Quiz

FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC

03/21/2024

Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...

Based on results from the phase...

03/21/2024

Oncology

Quiz

Repotrectinib for ROS1 Fusion-Positive NSCLC

02/05/2024

Oncology

Quiz

Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors

05/16/2023

How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?

How did patients with...

05/16/2023

Oncology

Quiz

Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC

04/17/2023

Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?

Did PD-L1 tumor proportion score...

04/17/2023

Oncology

Quiz

04/13/2023

Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?

Was combination nivolumab plus...

04/13/2023

Oncology

Quiz

First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC

02/15/2023

How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?

How did patients respond to...

02/15/2023

Oncology

Quiz

Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC

01/31/2023

Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?

Which survival outcomes did...

01/31/2023

Oncology

Recent News

News

Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer

08/19/2026

Emily Estrada

Results from the phase 2 DART...

08/19/2026

Oncology

News

Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer

08/11/2026

Emily Estrada

Ociperlimab plus tislelizumab...

08/11/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

News

Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer

05/29/2026

Stephanie Holland

Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.

Results from the phase 3...

05/29/2026

Oncology

News

Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer

05/27/2026

Emily Estrada

Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.

Updated results from the phase 3...

05/27/2026

Oncology

News

Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC

05/27/2026

Emily Estrada

Results from a multicenter phase...

05/27/2026

Oncology

FDA Approval

FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC

02/26/2026

Emily Estrada

Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.

Based on results from the...

02/26/2026

Oncology

News

Adjuvant Aumolertinib Improves Disease-Free Survival in Resected EGFR-Mutated Non–Small Cell Lung Cancer

01/21/2026

Stephanie Holland

Results from the phase 3 ARTS...

01/21/2026

Oncology

News

Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated Non-Small Cell Lung Cancer

01/13/2026

Stephanie Holland

Results from the phase 2 KANNON...

01/13/2026

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Amivantamab and Hyaluronidase

12/18/2025

Emily Estrada

On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.

On December 17, 2025, the FDA...

12/18/2025

Oncology

News

NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera

09/22/2026

Stephanie Holland

Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...

Updated NCCN Guidelines...

09/22/2026

Oncology

News

FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes

09/22/2026

Emily Estrada

The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...

The FDA granted Fast Track...

09/22/2026

Oncology

News

Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer

09/22/2026

Stephanie Holland

Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...

Results from the phase 3...

09/22/2026

Oncology

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology